UGT1A1*28 is associated with decreased systemic exposure of Atorvastatin lactone

Molecular Diagnosis and Therapy

Volumn 17, Issue 4, 2013, Pages 233-237

  Stormo, Camilla ^a   Bogsrud, Martin P ^b,c   Hermann, Monica ^b   Åsberg, Anders ^b   Piehler, Armin P ^d   Retterstøl, Kjetil ^c   Kringen, Marianne K ^e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Furst Medical Laboratory   (Norway)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ATORVASTATIN LACTONE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE; HEPTANOIC ACID DERIVATIVE; LACTONE; PYRROLE DERIVATIVE; UGT1A1 ENZYME;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG RECHALLENGE; DRUG WITHDRAWAL; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MYALGIA; MYOPATHY; PRIORITY JOURNAL; PYROSEQUENCING; RETROSPECTIVE STUDY; ALLELE; BLOOD; CHEMICALLY INDUCED DISORDER; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MIDDLE AGED; MUSCLE DISEASE; PATHOLOGY; CHEMICALLY INDUCED;

ADULT; ALLELES; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HEPTANOIC ACIDS; HUMANS; LACTONES; MALE; MIDDLE AGED; MUSCULAR DISEASES; POLYMORPHISM, GENETIC; PYRROLES;

EID: 84880778280     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0031-x     Document Type: Article

References (17)

1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.
2. Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33(3):171-87.
3. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy - a genome wide study. N Engl J Med. 2008;359(8):789-99.
4. Hermann M, Bogsrud MP, Molden E, et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther. 2006;79(6):532-9. (Pubitemid 43833450)
5. Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000;28(11):1369-78.
6. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005;33(4):537-46. (Pubitemid 40393197)
7. Skottheim IB, Gedde-Dahl A, Hejazifar S, et al. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci. 2008;33(4-5):317-25.
8. Skottheim IB, Bogsrud MP, Hermann M, et al. Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy. Mol Diagn Ther. 2011;15(4):221-7.
9. Riedmaier S, Klein K, Hofmann U, et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther. 2010;87(1):65-73.
10. Cho SK, Oh ES, Park K, et al. The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers. Pharmacogenet Genomics. 2012;22(8):598-605.
11. Court MH. Michael H. Court's (2005-2008) online calculator. Tufts University web site. 2 May 22011. http://www.tufts.edu/~mcourt01/Documents/ Court%20lab%20-%20HW%20calculator.xls. Accessed 26 Mar 2012.
12. Carter KW, McCaskie PA, Palmer LJ. JLIN: a java based linkage disequilibrium plotter. BMC Bioinforma. 2006;7:60.
13. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002;30(5):505-12. (Pubitemid 34456970)
14. Iolascon A, Faienza MF, Centra M, et al. (TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome. Haematologica. 1999;84(2):106-9. (Pubitemid 29479654)
15. Laaksonen R. On the mechanisms of statin-induced myopathy. Clin Pharmacol Ther. 2006;79(6):529-31. (Pubitemid 43817946)
16. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609-16.
17. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998;95(14):8170-4. (Pubitemid 28326085)